A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?

Transaction worth based connected SEC Form 4 weighted mean prices ($39.15 connected March 3; $39.67 connected March 4); post-transaction worth based connected March 4, 2026 marketplace adjacent ($34.00).

• Was the transaction executed via nonstop oregon indirect ownership, and what entities were involved? All shares were disposed of indirectly done Opaleye, L.P. and a separately managed account, with Opaleye Management Inc. acting arsenic concern manager and portfolio manager, respectively. No nonstop stock transactions occurred.

• Does Opaleye Management Inc. clasp a worldly presumption successful Harrow pursuing this transaction? Yes. Following the sale, Opaleye L.P. holds 3,622,000 shares and the managed relationship holds 59,428 shares, for a combined indirect presumption of astir 3.68 cardinal shares.

*1-year terms alteration calculated arsenic of March 23, 2026.

Harrow is simply a starring ophthalmic pharmaceutical institution focused connected the discovery, development, and commercialization of eye-care products for the North American market. Its portfolio of branded products includes VEVYE for adust oculus disease, IHEEZO for ocular anesthesia, and TRIESENCE for ocular inflammation, arsenic good arsenic ImprimisRx, its ophthalmology-focused compounded medications division.

The institution generates gross done the merchantability of branded and specialty ophthalmic drugs and compounded pharmaceutical products. Primary customers see ophthalmologists, outpatient surgical centers, hospitals, and specialty healthcare providers. Harrow reported full-year 2025 gross of $272.3 cardinal -- a 36% summation implicit 2024 -- and guided 2026 gross to a scope of $350-$365 million.

On its face, a merchantability of astir $8 cardinal worthy of banal sounds similar a important ballot of no-confidence -- but the discourse present is much nuanced.

The timing is worthy noting. Harrow reported Q4 2025 net connected March 2 -- the time earlier Opaleye began selling. The institution missed expert EPS estimates by a wide margin, and the banal dropped sharply. Selling into that benignant of post-earnings weakness looks much similar opportunistic profit-taking aft a beardown anterior tally than a cardinal alteration successful outlook.